Natural killer/T‑cell lymphoma‑associated hemophagocytic syndrome: A case report

Han,Lijuan; Zhang,Mingzhi; Li,Ling; Zhang,Lei; Wu,Jingjing; Li,Xin; Wang,Xinhua; Young,Ken.  H.; Fu,Xiaorui; Ma,Wang; Sun,Zhenchang; Zhang,Xudong; Chang,Yu; Qiao,Zhi

doi:10.3892/ol.2014.2202

August-2014 Volume 8 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2014 Volume 8 Issue 2

Full Size Image

Case Report

Natural killer/T‑cell lymphoma‑associated hemophagocytic syndrome: A case report

Authors:
- Lijuan Han
- Mingzhi Zhang
- Ling Li
- Lei Zhang
- Jingjing Wu
- Xin Li
- Xinhua Wang
- Ken. H. Young
- Xiaorui Fu
- Wang Ma
- Zhenchang Sun
- Xudong Zhang
- Yu Chang
- Zhi Qiao
View Affiliations / Copyright

Affiliations: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX 77230‑1439, USA
Pages: 886-890
|
Published online on: May 30, 2014

https://doi.org/10.3892/ol.2014.2202
Expand metrics +

Abstract

Natural killer (NK)/T‑cell lymphoma‑associated hemophagocytic syndrome (HPS) is a rare and fatal disease with no optimal treatment. The present study reports the clinical features, diagnosis and treatment process of three patients with relapsed NK/T‑cell lymphoma‑associated HPS. All of the patients were classified as Ann Arbor stage IV and presented with a poor performance status. Two patients were successfully treated with a pegaspargase‑containing combination regimen and one patient succumbed due to serious complications. These cases indicate that for patients with a history of lymphoma, the diagnosis of HPS should be considered when patients present with progressive high fever, pancytopenia and liver dysfunction. Early identification and effective treatments, including pegaspargase‑based regimens are essential for an enhanced prognosis.

View Figures

View References

1	Chim CS, Ma SY, Au WY, et al: Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 103:216–221. 2004.
2	Szyper-Kravitz M: The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm. Isr Med Assoc J. 11:633–634. 2009.
3	Henter JI, Horne A, Aricó M, et al: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 48:124–131. 2007.
4	Janka GE: Hemophagocytic syndromes. Blood Rev. 21:245–253. 2007.
5	Han AR, Lee HR, Park BB, et al: Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol. 86:493–498. 2007.
6	Chuang HC, Lay JD, Hsieh WC and Su IJ: Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci. 98:1281–1287. 2007.
7	Chuang HC, Lay JD, Chuang SE, Hsieh WC, Chang Y and Su IJ: Epstein-Barr virus (EBV) latent membrane protein-1 down-regulates tumor necrosis factor-alpha (TNF-alpha) receptor-1 and confers resistance to TNF-alpha-induced apoptosis in T cells: implication for the progression to T-cell lymphoma in EBV-associated hemophagocytic syndrome. Am J Pathol. 170:1607–1617. 2007.
8	Ost A, Nilsson-Ardnor S and Henter JI: Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis. Histopathology. 32:310–316. 1998.
9	Chauchet A, Michallet AS, Berger F, et al: Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma. J Hematol Oncol. 5:272012.
10	Kwong YL, Kim WS, Lim ST, et al: SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 120:2973–2980. 2012.
11	Douer D, Yampolsky H, Cohen LJ, et al: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 109:2744–2750. 2007.
12	Lim ST, Fei G, Quek R, et al: The relationship of hepatitis B virus infection and non-Hodgkin’s lymphoma and its impact on clinical characteristics and prognosis. Eur J Haematol. 79:132–137. 2007.
13	Li YH, He YF, Jiang WQ, et al: Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 106:1320–1325. 2006.
14	Hoofnagle JH, Dusheiko GM, Schafer DF, et al: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 96:447–449. 1982.
15	Trottestam H, Horne A, Aricó M, et al: Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 118:4577–4584. 2011.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Natural killer/T‑cell lymphoma‑associated hemophagocytic syndrome: A case report

This article is mentioned in:

Abstract

Related Articles